Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy

Stacey Schultz-Cherry, Maureen A McGargill, Paul G Thomas, Jeremie H Estepp, Aditya H Gaur, E Kaitlynn Allen, Kim J Allison, Li Tang, Richard J Webby, Sean D Cherry, Chun-Yang Lin, Thomas Fabrizio, Elaine I Tuomanen, Joshua Wolf, SJTRC Investigative Team, Ericka Kirkpatrick Roubidoux, Pamela Freiden, Tomi Mori, Diego R Hijano, Hana Hakim, David C Brice, Ashley Castellaw, Florian Krammer, David E Wittman, Jason Hodges, Ronald H Dallas, Valerie Cortez, Ana Vazquez-Pagan, Resha Bajracharya, Brandi L Clark, Lee-Ann Van de Velde, Walid Awad, Taylor L Wilson, Allison M Kirk, Randall T Hayden, James Hoffman, Jamie Russell-Bell, James Sparks, Stacey Schultz-Cherry, Maureen A McGargill, Paul G Thomas, Jeremie H Estepp, Aditya H Gaur, E Kaitlynn Allen, Kim J Allison, Li Tang, Richard J Webby, Sean D Cherry, Chun-Yang Lin, Thomas Fabrizio, Elaine I Tuomanen, Joshua Wolf, SJTRC Investigative Team, Ericka Kirkpatrick Roubidoux, Pamela Freiden, Tomi Mori, Diego R Hijano, Hana Hakim, David C Brice, Ashley Castellaw, Florian Krammer, David E Wittman, Jason Hodges, Ronald H Dallas, Valerie Cortez, Ana Vazquez-Pagan, Resha Bajracharya, Brandi L Clark, Lee-Ann Van de Velde, Walid Awad, Taylor L Wilson, Allison M Kirk, Randall T Hayden, James Hoffman, Jamie Russell-Bell, James Sparks

Abstract

The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference" might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting.

Trial registration: The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https://ichgcp.net/clinical-trials-registry/NCT04362995.

Keywords: COVID-19; SARS-CoV-2; antibody; bamlanivimab; vaccine failure.

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
A, Timeline of events. MAb, COVID-19-specific monoclonal antibody therapy (Bamlanivimab, Eli Lilly, Indianapolis, Indiana, USA); Vaccine, mRNA COVID-19 vaccine (BNT162b2, Pfizer-BioNTech, Philadelphia, Pennsylvania, USA). B, Antibody responses against receptor binding domain for common SARS-CoV-2 variants after infection/monoclonal antibody therapy and COVID-19 vaccine show increases in variant-specific antibodies after vaccination. V1 and V2, administration of first and second doses of mRNA COVID-19 vaccine (BNT162b2 OD490, RBD-specific antibody level measured by ELISA as optical density at 490 nm. Abbreviations: COVID-19, coronavirus disease 2019; ELISA, enzyme-linked immunosorbent assay; MAb, monoclonal antibody; PCR, polymerase chain reaction; RBD, receptor binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 2.
Figure 2.
Vaccination with COVID-19 vaccine after treatment of COVID-19 with monoclonal antibody is associated with similar RBD antibody responses to vaccination following COVID-19 alone. OD490, RBD antibody levels by ELISA measured as optical density at 490 nm; Red dot, Participant vaccinated with mRNA COVID-19 vaccine following natural infection and monoclonal antibody therapy (Postvaccine dose #1, sample collected 21 days after vaccine and 41 days after symptom onset; Postvaccine dose #2, sample collected 40 days after vaccine and 81 days after symptom onset); Gray dots, participants with vaccination following natural infection only (Postvaccine dose #1, sample collected 14–21 days after vaccine; Postvaccine dose #2, sample collected 23–56 days after vaccine; Dashed line, median. Abbreviations: COVID-19, coronavirus disease 2019; ELISA, enzyme-linked immunosorbent assay; RBD, receptor binding domain.

References

    1. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020; 396:1595–606.
    1. Robbiani DF, Gaebler C, Muecksch F, et al. . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020; 584:437–42.
    1. Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. Available at: . Accessed 4 September 2021.
    1. Hoffmann M, Arora P, Groß R, et al. . SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 2021; 184:2384-2393.e12.
    1. Vidal SJ, Collier AY, Yu J, et al. . Correlates of neutralization against SARS-CoV-2 variants of concern by early pandemic sera. J Virol 2021; 95:e0040421.
    1. Food and Drug Administration. Fact sheet for health care providers; emergency use authorization (EUA) of bamlanivimab. Available at: . Accessed 30 November 2020.
    1. World Health Organization. Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing. Available at: . Accessed 19 May 20121.
    1. Food and Drug Administration. Fact sheet for health care providers; Emergency Use Authorization (EUA) of casirivimab and imdevimab. Available at: . Accessed 30 November 2020.
    1. Food and Drug Administration. Fact sheet for health care providers; Emergency Use Authorization (EUA) of bamlanivimab and etesevimab. Available at: . Accessed 27 April 2021.
    1. Infectious Diseases Society of America. IDSA guidelines on the treatment and management of patients with COVID-19. Available at: . Accessed 27 April 2021.
    1. Regeneron Pharmaceuticals Inc. Phase 3 prevention trial showed 81% reduced risk of symptomatic SARS-CoV-2 infections with subcutaneous administration of REGEN-COV™ (casirivimab with imdevimab). Available at: . Accessed 12 April 2021.
    1. Harris PA, Taylor R, Minor BL, et al. ; REDCap Consortium. The REDCap Consortium: building an international community of software platform partners. J Biomed Inform 2019; 95:103208.
    1. Harris PA, Taylor R, Thielke R, et al. . Research Electronic Data Capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–81.
    1. Amanat F, Stadlbauer D, Strohmeier S, et al. . A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med 2020; 26:1033–6.
    1. Siber GR, Werner BG, Halsey NA, et al. . Interference of immune globulin with measles and rubella immunization. J Pediatr 1993; 122:204–11.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren